Related Experiment Video
Updated: Jul 27, 2026

A Rat Model of Pouchitis Following Proctocolectomy and Ileal Pouch-Anal Anastomosis Using Dextran Sulfate Sodium
Published on: May 31, 2024
[Persistent diarrhea]
J A Andrade1, C Moreira, U Fagundes Neto
1Universidade de São Paulo (USP), São Paulo, SP, Brazil.
Insights
Persistent diarrhea, lasting over 14 days, significantly impacts child health in developing nations. Early intervention and exclusive breastfeeding are key to managing and preventing this severe condition in infants.
Area of Science:
- Pediatrics
- Infectious Diseases
- Public Health
Background:
- Persistent diarrhea affects 3-20% of children under five in developing countries.
- Defined as diarrhea lasting longer than 14 days, it contributes significantly to infant morbidity and mortality.
- Etiological agents include Enteropathogenic E. coli (EPEC), Salmonella, Enteroaggregative E. coli (EAEC), Klebisiella, and Cryptosporidium.
Purpose of the Study:
- To define persistent diarrhea and outline its etiology, clinical aspects, therapy, and prevention.
- To highlight the multifactorial nature of persistent diarrhea, involving host factors and environmental contamination.
- To emphasize the importance of prompt treatment and preventive strategies.
Main Methods:
- Review of existing studies on persistent diarrhea in children under five.
- Analysis of etiological agents, clinical presentations, and treatment outcomes.
- Evaluation of preventive measures, particularly breastfeeding.
Main Results:
- Clinical characteristics of persistent diarrhea are generally consistent across different pathogenic agents.
- Persistent diarrhea results from a combination of host vulnerabilities and environmental contamination.
- Oral rehydration therapy and appropriate early feeding are effective in managing most cases.
Conclusions:
- Prompt treatment of all diarrhea episodes with appropriate follow-up is crucial.
- Preventive strategies, especially promoting exclusive breastfeeding, are vital for reducing diarrheal disease.
- Integrated management addressing both treatment and prevention is essential for combating persistent diarrhea.
Abstract:
INTRODUCTION: Persistent diarrhea has high impact on infantile morbidity and mortality rates in developing countries. Several studies have shown that 3 to 20% of acute diarrheal episodes in children under 5 years of age become persistent. DEFINITION: Persistent diarrhea is defined as an episode that lasts more than 14 days. ETIOLOGY: The most important agents isolated in persistent diarrhea are: Enteropathogenic E. coli (EPEC), Salmonella, Enteroaggregative E. coli (EAEC), Klebisiella and Cryptosporidium. CLINICAL ASPECTS: In general, the clinical characteristics of patients with persistent diarrhea do not change with the pathogenic agent. Persistent diarrhea seems to represent the final result of a several insults a infant suffers that predisposes to a more severe episode of diarrhea due to a combination of host factors and high rates of enviromental contamination. Therefore, efforts should be made to promptly treat all episodes of diarrhea with apropriate follow-up. THERAPY: The aim of the treatment is to restore hydroelectrolytic deficits and to replace losses until the diarrheal ceases. It is possible in the majority of the cases, using oral rehydration therapy and erly an appropriate type of diet. PREVENTION: It is imperative that management strategies also focus on preventive aspects. The most effective diarrheal prevention strategy in young infants worldwide is promotion of exclusive breast feeding.
Related Concept Videos
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Bacterial Gastroenteritis
Giardiasis
Inflammatory Bowel Disease I: Introduction

